Dare Bioscience announced that it will implement a 1-for-12 reverse split of the issued shares of its common stock, effective on July 1, 2024. The Company’s common stock is expected to begin trading on a split-adjusted basis when the market opens on Monday, July 1, 2024, and will continue to trade on The Nasdaq Capital Market under the symbol “DARE.” The reverse stock split is intended to increase the bid price of the common stock to enable the Company to regain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DARE:
- Dare announces publication of efficacy results of topical sildenafil cream
- Biotech Alert: Searches spiking for these stocks today
- Brookline upgrades Dare Bioscience to Buy on improved funding
- Dare Bioscience upgraded to Buy from Hold at Brookline
- Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update